Skip to main content
Evidence Snapshot

Dual specificity protein kinase CLK1

CHEMBL4224 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T03:29:42Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4224
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dual specificity protein kinase CLK1 as ChEMBL target CHEMBL4224, mapped to UniProt P49759. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Dual specificity protein kinase CLK1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4224
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P49759
Dual specificity protein kinase CLK1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Dual specificity protein kinase CLK1 matters

As of 2026-09-13

Dual specificity protein kinase CLK1 is reviewed as Dual specificity protein kinase CLK1 (UniProt P49759); the current evidence base includes 22 approved drugs, 2079 compounds, and 515 assays, with lead potency reaching pChEMBL 10.7.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 22 approved drugs, 2079 compounds, and 515 assays for this target. The dominant activity type is IC50. CHEMBL4784318 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL4784318 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine
22 approved pChEMBL 10.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Dual specificity protein kinase CLK1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P49759, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2079
Total Compounds
515
Total Assays
22
Approved Drugs
IC50: 1182.0, KI: 8.0, EC50: 45.0, KD: 431.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4784318
 10.7 Kd —
No preferred name
CHEMBL393525
 10.2 Kd —
No preferred name
CHEMBL5653589
 9.7 Kd —
No preferred name
CHEMBL4441878
 9.6 Kd —
No preferred name
CHEMBL4647659
 9.6 Kd —

Approved Drugs

Structure Compound First Approval
TOVORAFENIB
CHEMBL3348923
 2024
CAPIVASERTIB
CHEMBL2325741
 2023
MOMELOTINIB
CHEMBL1078178
 2023
PACRITINIB
CHEMBL2035187
 2022
ABEMACICLIB
CHEMBL3301610
 2017
BRIGATINIB
CHEMBL3545311
 2017
MIDOSTAURIN
CHEMBL608533
 2017
BARICITINIB
CHEMBL2105759
 2017
PALBOCICLIB
CHEMBL189963
 2015
NINTEDANIB
CHEMBL502835
 2014
BOSUTINIB
CHEMBL288441
 2012
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T03:29:42Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4224